Bristol Myers Squibb (BMY) Prepaid Assets (2009 - 2026)
Bristol Myers Squibb (BMY) reported Prepaid Assets of $4.6 billion for Q1 2026, down 16.93% year-over-year from $5.5 billion in Q1 2025, and little changed on a QoQ basis from $4.6 billion in Q4 2025.
Bristol Myers Squibb (BMY) has 18 years of Prepaid Assets data on file, last reported at $4.6 billion in Q1 2026.
- Quarterly Prepaid Assets fell 16.93% year-over-year to $4.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.6 billion (down 16.93% YoY) and the FY2025 annual result came in at $4.6 billion, down 17.87% from the prior year.
- Prepaid Assets was little changed at $4.6 billion in Q1 2026 per BMY's latest filing, from $4.6 billion in the prior quarter.
- Across five years, Prepaid Assets topped out at $7.2 billion in Q3 2023 and bottomed at $4.5 billion in Q1 2022.
- The 5-year median for Prepaid Assets is $5.6 billion (2024), against an average of $5.6 billion.
- The widest annual swing landed in 2022, when Prepaid Assets jumped 39.11%; it then dropped 21.98% in 2024.
- Tracing BMY's Prepaid Assets over 5 years: stood at $5.8 billion in 2022, then climbed by 1.93% to $5.9 billion in 2023, then declined by 4.91% to $5.6 billion in 2024, then retreated by 17.87% to $4.6 billion in 2025, then decreased by 0.35% to $4.6 billion in 2026.
- Per Business Quant, the three latest BMY Prepaid Assets figures stand at $4.6 billion (Q1 2026), $4.6 billion (Q4 2025), and $4.9 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.60 Bn |
| Dec 31, 2025 | 4.61 Bn |
| Sep 30, 2025 | 4.95 Bn |
| Jun 30, 2025 | 5.47 Bn |
| Mar 31, 2025 | 5.53 Bn |
| Dec 31, 2024 | 5.62 Bn |
| Sep 30, 2024 | 5.62 Bn |
| Jun 30, 2024 | 5.74 Bn |
| Mar 31, 2024 | 5.57 Bn |
| Dec 31, 2023 | 5.91 Bn |
| Sep 30, 2023 | 7.21 Bn |
| Jun 30, 2023 | 6.87 Bn |
| Mar 31, 2023 | 5.16 Bn |
| Dec 31, 2022 | 5.80 Bn |
| Sep 30, 2022 | 6.08 Bn |
| Jun 30, 2022 | 5.76 Bn |
| Mar 31, 2022 | 4.54 Bn |
| Dec 31, 2021 | 4.83 Bn |
| Sep 30, 2021 | 4.37 Bn |
| Jun 30, 2021 | 5.04 Bn |
| Mar 31, 2021 | 3.57 Bn |
| Dec 31, 2020 | 3.79 Bn |
| Sep 30, 2020 | 3.11 Bn |
| Jun 30, 2020 | 2.45 Bn |
| Mar 31, 2020 | 2.41 Bn |
| Dec 31, 2019 | 1.98 Bn |
| Sep 30, 2019 | 947.00 Mn |
| Jun 30, 2019 | 1.38 Bn |
| Mar 31, 2019 | 1.34 Bn |
| Dec 31, 2018 | 2.02 Bn |
| Sep 30, 2018 | 886.00 Mn |
| Jun 30, 2018 | 998.00 Mn |
| Mar 31, 2018 | 965.00 Mn |
| Dec 31, 2017 | 576.00 Mn |
| Sep 30, 2017 | 754.00 Mn |
| Jun 30, 2017 | 820.00 Mn |
| Mar 31, 2017 | 628.00 Mn |
| Dec 31, 2016 | 570.00 Mn |
| Sep 30, 2016 | 565.00 Mn |
| Jun 30, 2016 | 588.00 Mn |
| Mar 31, 2016 | 615.00 Mn |
| Dec 31, 2015 | 625.00 Mn |
| Sep 30, 2015 | 529.00 Mn |
| Jun 30, 2015 | 502.00 Mn |
| Mar 31, 2015 | 538.00 Mn |
| Dec 31, 2014 | 470.00 Mn |
| Sep 30, 2014 | 482.00 Mn |
| Jun 30, 2014 | 512.00 Mn |
| Mar 31, 2014 | 538.00 Mn |
| Dec 31, 2013 | 412.00 Mn |
| Sep 30, 2013 | 556.00 Mn |
| Jun 30, 2013 | 536.00 Mn |
| Mar 31, 2013 | 616.00 Mn |
| Dec 31, 2012 | 355.00 Mn |
| Sep 30, 2012 | 423.00 Mn |
| Jun 30, 2012 | 455.00 Mn |
| Mar 31, 2012 | 500.00 Mn |
| Dec 31, 2011 | 258.00 Mn |
| Sep 30, 2011 | 356.00 Mn |
| Jun 30, 2011 | 420.00 Mn |
| Mar 31, 2011 | 451.00 Mn |
| Dec 31, 2010 | 252.00 Mn |
| Dec 31, 2009 | 256.00 Mn |
| Sep 30, 2009 | 493.00 Mn |
| Jun 30, 2009 | 385.00 Mn |